Clinical and Pathological Features of Prostatic Stromal Tumor of Uncertain Malignant Potential: A Retrospective Study of 23 Chinese Cases

2020 ◽  
pp. 1-9
Author(s):  
Qi Shen ◽  
Zhaohui Zhou ◽  
Zhenhua Liu ◽  
Shuai Hu ◽  
Zhiyong Lin ◽  
...  
Keyword(s):  
Disease Progression ◽  
Rare Disease ◽  
Subgroup Analysis ◽  
Specific Antigen ◽  
Malignant Potential ◽  
Stromal Tumor ◽  
Uncertain Malignant Potential ◽  
Stromal Sarcoma ◽  
The Mean

<b><i>Introduction:</i></b> Prostatic stromal tumor of uncertain malignant potential (STUMP) is a rare disease that may coexist with prostate stromal sarcoma (PSS). We aimed to analyze the histological and clinical features of STUMP. <b><i>Methods:</i></b> Twenty-three patients diagnosed with STUMP from 2008 to 2019 were included. Clinicopathological and follow-up information was collected. In the subgroup analysis, we divided the patients into a pure STUMP group (<i>N</i> = 18) and a mixed STUMP (STUMP coexisting with PSS) group (<i>N</i> = 5). Student’s <i>t</i> test was used to compare the 2 groups. <b><i>Results:</i></b> Patients had a mean age of 55.5 ± 19.4 years and an average follow-up time of 42.3 months. The mean prostate volume was 109.2 ± 73.5 cm<sup>3</sup>, and the mean prostate-specific antigen was 8.03 ± 10.5 ng/mL. In the subgroup analysis, 16.7% (2/12) of pure STUMP patients had disease progression, while 100% (3/3) of mixed STUMP patients suffered from recurrence. Compared with the pure STUMP group, the mixed STUMP group was younger (37.2 vs. 60.6 years, <i>p</i> = 0.013) and had lower expression of estrogen receptor and progesterone receptor (<i>p</i> = 0.004 and <i>p</i> &#x3c; 0.001, respectively). <b><i>Conclusion:</i></b> STUMP is a rare disease with a relatively good prognosis. However, there is still a possibility of disease progression or coexistence with stromal sarcoma. Timely diagnosis and regular monitoring may be helpful in improving treatment outcomes.

Incidental Prostatic Stromal Tumor of Uncertain Malignant Potential (STUMP): Histopathological and Immunohistochemical Findings

2012 ◽  
Vol 79 (1) ◽  
pp. 65-68 ◽  
Author(s):  
Ettore De Berardinis ◽  
Gian Maria Busetto ◽  
Gabriele Antonini ◽  
Riccardo Giovannone ◽  
Mariarosaria Di Placido ◽  
...  
Keyword(s):  
Prostate Gland ◽  
Digital Rectal Examination ◽  
Radical Retropubic Prostatectomy ◽  
Malignant Potential ◽  
Stromal Tumor ◽  
Uncertain Malignant Potential ◽  
Transperineal Prostate Biopsy ◽  
Stromal Sarcoma ◽  
Long Term Follow Up

Stromal prostate tumors are rare neoplastic proliferative lesions that have been classified into prostatic stromal tumor of uncertain malignant potential (STUMP) and prostatic stromal sarcoma (SS) based on these criteria: stromal cellularity, presence of mitotic figures, necrosis, and stromal overgrowth. A prostatic stromal tumor of uncertain malignant potential (STUMP) is a non-epithelial, mesenchymal spindle-cell tumor that can be classified as a specialized stromal tumor of the prostate. STUMPs have the capability to diffusely infiltrate the prostate gland and extend into adjacent tissues. Furthermore, they often recur and this is why they are considered as neoplastic entities. STUMPs usually tend to be not aggressive, but occasional cases have been reported with an extension into adjacent tissues. A few cases develop a sarcomatous dedifferentiation. A 67-year-old male referred to the Department of Urology, Sapienza Rome University, with acute urinary retention (AUR) and bladder overdistention. Digital rectal examination (DRE) showed the presence of a severe prostatic hyperplasia and a transvesical prostatic adenomectomy (TVPA) was performed. The pathological evaluation performed at the Department of Pathology, Sapienza Rome University, revealed an incidental diagnosis of prostatic STUMP. The patient's follow-up is made every year with transrectal ultrasonography and nuclear magnetic resonance with spectroscopy, and every two years with a transperineal prostate biopsy to exclude a progression to a stromal sarcoma. After 5 years of follow-up the STUMP is still detectable but there is no sign of sarcoma. As a result of its relative rarity and lack of long-term follow-up, the prognosis of STUMP is unclear. Therapy varies from a wait-and-see approach to a radical retropubic prostatectomy.

scholarly journals Prostatic Stromal Tumor of Uncertain Malignant Potential Which Was Difficult to Diagnose

2015 ◽  
Vol 2015 ◽  
pp. 1-5
Author(s):  
Satoko Matsuyama ◽  
Takahiro Nohara ◽  
Shohei Kawaguchi ◽  
Chikashi Seto ◽  
Yuko Nakanishi ◽  
...  
Keyword(s):  
Transurethral Resection ◽  
Digital Rectal Examination ◽  
Radical Resection ◽  
Final Diagnosis ◽  
Malignant Potential ◽  
Stromal Tumor ◽  
Prostatic Urethra ◽  
Uncertain Malignant Potential ◽  
Stromal Sarcoma ◽  
Stromal Tissue

Here, we report a case of stromal tumor of uncertain malignant potential (STUMP) that was difficult to diagnose. A 53-year-old male was found to have a hard nodule on digital rectal examination; magnetic resonance imaging revealed a large nodule on the left side of the prostate, indicating prostate cancer. However, pathological diagnosis of the biopsy specimen was benign prostatic hyperplasia. Although a papillary tumor in the prostatic urethra was also seen on urethrocystoscopy, the tumor specimen obtained from transurethral resection was not malignant. The tumor in the prostatic urethra recurred only 3 months after transurethral resection, and pathological findings revealed benign hyperplasia not only in the stromal tissue but also in the epithelium; therefore, the prostate tumor was suspected to be STUMP. It took many prostate pathologists a long time to reach the final diagnosis of STUMP. STUMP is a rare benign tumor, difficult to diagnose, and sometimes transforms into stromal sarcoma. Thus, we should consider radical resection in such cases.

Low dose enzalutamide in metastatic castration-resistant prostate cancer: A retrospective Caribbean study.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e16548-e16548
Author(s):  
Vincent Vinh-Hung ◽  
Kadiatou Diakite ◽  
Clarisse Joachim ◽  
Stefanos Bougas ◽  
Cristina Ioana Furtos ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Disease Progression ◽  
Selection Criteria ◽  
Low Dose ◽  
Specific Antigen ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Psa Response ◽  
The Mean

e16548 Background: There is scarce information on the efficacy of low-dose enzalutamide in metastatic castration-resistant prostate cancer. We report on a series treated with half dose enzalutamide. Methods: We observed a trend in our practice to initiate low-dose enzalutamide at the time of disease progression in older patients considered frail, presenting with cardio-vascular comorbidity or with history of neurological symptoms. Records were retrospectively reviewed. The selection criteria were: 1) Metastatic disease demonstrated by at least one imaging modality, CT, bone scan, or positron emission tomography. 2) Progression of prostate specific antigen (PSA). 3) Castrate testosterone level ( < 0.2 ng/mL). 4) Enzalutamide treatment at 80 mg or less, once daily. To estimate the rate of PSA response, we used linear interpolation to compute the time from the initiation of low-dose enzalutamide to 50% PSA reduction. Results: Between November 2015 and December 2018 at the Martinique University Hospital, 10 patients matching the selection criteria were treated with ≤ 80 mg enzalutamide od: 8 started de novo with the low dose, 2 started with 160 mg but required dose reduction for intolerance. The mean age was 78 years (range 67-84). Three had painful bone metastases. The mean PSA at start of low dose enzalutamide was 88 ng/mL (range 1.06 - 251.8). All patients were maintained with reduced dose. At the current follow-up of 9 months (range 0 - 36 months), PSA response was observed in 7 patients ( = 70%), 1 was not evaluable (PSA not assessed), 2 did not respond. Of the 2 non-responders, one had no sign or symptom of disease progression; the other presented with extensive disease progression previously treated with abiraterone, he refused to receive increased dose enzalutamide. Among the 7 responders, the time to 50% PSA reduction was 57 days (range 26 - 119). Currently, the decline of PSA remains sustained in 6 of the 7 responders, it increased in 1 who discontinued enzalutamide. Pain decreased in the 3 symptomatic patients, including the PSA non-responder. Conclusions: Low dose enzalutamide appears efficient in a large proportion of selected frail patients. Further follow-up is required to evaluate the long-term response.

Stromal Tumor of Uncertain Malignant Potential of the Prostate

2014 ◽  
Vol 138 (11) ◽  
pp. 1542-1545 ◽  
Author(s):  
Lauren M. Murer ◽  
Geoffrey A. Talmon
Keyword(s):  
Aggressive Behavior ◽  
Distant Metastasis ◽  
Surgical Intervention ◽  
Clinical Course ◽  
Malignant Potential ◽  
Stromal Tumor ◽  
Rare Tumor ◽  
Uncertain Malignant Potential ◽  
Stromal Sarcoma

Stromal tumor of uncertain malignant potential (STUMP) of the prostate is a rare tumor with a variable and unpredictable clinical course. Many STUMPs are diagnosed incidentally and never progress, while others may invade locally and rapidly recur after surgical intervention, and yet others may lead to distant metastasis and death. A wide array of histologic patterns is encompassed by STUMP, and distinguishing these tumors from prostatic stromal sarcoma or other causes of stromal expansion often proves difficult. Owing to the rarity of this tumor, there is not yet a consensus on appropriate management. However, owing to the possibility of aggressive behavior, close management and consideration of definitive resection is warranted.

scholarly journals Proliferações Melanocíticas de Potencial Maligno Incerto: Um Estudo Retrospetivo de 23 Doentes

2020 ◽  
Vol 77 (4) ◽  
pp. 305-309
Author(s):  
Jorge Lopes ◽  
Cristina Sousa ◽  
Diogo Teixeira ◽  
David Tente ◽  
Armando Baptista ◽  
...  
Keyword(s):  
Lymph Node Biopsy ◽  
Malignant Potential ◽  
Uncertain Malignant Potential ◽  
Diagnostic Uncertainty ◽  
Melanocytic Lesions ◽  
The Subject ◽  
The Mean ◽  
Dichotomous Classification

Introduction: Diagnostic uncertainty is an inseparable component of medical practice. The dichotomous classification of melanocytic lesions as benign or malignant has been replaced in recent years by a more flexible approach in which diagnostic uncertainty is recognized and accepted. Methods: In order to characterize the population of melanocytic proliferations of uncertain malignant potential diagnosed at our center between 2007 and 2017, histopathological reports of melanocytic lesions classified, in this period, as either dysplastic or malignant were analyzed. Results: Twenty-three lesions (4.3%) with borderline histopathological features or uncertain malignant potential were identified. The mean patient age was 34.8 years. Sixteen lesions (69.6%) were observed by a second pathologist. The most frequently performed treatment was wide excision. A sentinel lymph node biopsy was performed on 2 patients, both being negative. The median follow-up time was 22 months, and there was no recurrence of any treated lesion. Discussion: The controversy of the subject extends from the nature and classification of these lesions to their treatment. In this work we perform a statistical review of the population of melanocytic proliferations of uncertain malignant potential diagnosed in our department.

Recurrent Prostatic Stromal Tumor of Uncertain Malignant Potential Combined with Concurrent Prostatic Adenocarcinoma: An Unusual Case

2021 ◽  
pp. 1-5
Author(s):  
Zhen Zhang ◽  
Chaozhao Liang
Keyword(s):  
Transurethral Resection ◽  
Unusual Case ◽  
Malignant Potential ◽  
Prostatic Adenocarcinoma ◽  
Stromal Tumor ◽  
Simultaneous Occurrence ◽  
Uncertain Malignant Potential ◽  
Unique Case ◽  
Neoplastic Lesions

Prostatic stromal tumor of uncertain malignant potential (STUMP), characterized by an atypical, unique stromal proliferation of the prostate, is often difficult to be differentiated from other nonepithelial neoplastic lesions. We present a unique case of recurrent STUMP after transurethral resection of the prostate (TURP) with concurrent prostatic adenocarcinoma. Patients diagnosed with prostatic STUMP should be followed up closely, for it may recur and invade adjacent organs after TURP shortly. Concurrent prostatic adenocarcinoma can be found in STUMP patients, and there may be some potential mechanisms which promote the simultaneous occurrence of the 2 tumors.

scholarly journals Minimally invasive treatment options to borderline ovarian tumors

2016 ◽  
Author(s):  
Punita Bhardwaj ◽  
T. K. Das ◽  
S. Batra ◽  
Keyword(s):  
Early Stage ◽  
Treatment Options ◽  
Malignant Potential ◽  
Ovarian Tumors ◽  
Conservative Approach ◽  
Uncertain Malignant Potential ◽  
Invasive Treatment ◽  
Younger Women ◽  
Borderline Ovarian Tumors

Borderline Ovarian tumors are tumors of uncertain malignant potential. They have favour able prognosis. They occur in younger women and present at an early stage. They are difficult to diagnose preoperatively as macroscopic picture is a combination of benign and invasive ovarian tumors. Over the years surgical treatment has changed from radical to conservative approach without overlooking oncologic safety. Follows up is essential. Prolonged follow up (>10 yrs) is required because of later recurrences. Special attention is to be paid to the conserved ovary in follow up.

Sign in / Sign up

Export Citation Format

Share Document